Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Acacia Pharma Group plc
  6. Summary
    ACPH   GB00BYWF9Y76

ACACIA PHARMA GROUP PLC

(ACPH)
  Report
Real-time Quote. Real-time Euronext Bruxelles - 01/21 11:35:19 am
1.36 EUR   -2.16%
2021Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust
AQ
2021ACACIA PHARMA GROUP PLC : Crossing thresholds
CO
2021CORRECTION : Issue of Shares to Employee Benefit Trust
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
1.45(c) 1.43(c) 1.43(c) 1.39(c) 1.36(c) Last
28 209 40 729 62 529 160 651 152 870 Volume
-1.36% -1.38% 0.00% -2.80% -2.16% Change
More quotes
Estimated financial data (e)
Sales 2021 1,18 M 1,60 M 1,60 M
Net income 2021 -37,5 M -50,9 M -50,9 M
Net cash position 2021 2,72 M 3,68 M 3,68 M
P/E ratio 2021 -2,97x
Yield 2021 -
Sales 2022 17,8 M 24,2 M 24,2 M
Net income 2022 -40,4 M -54,8 M -54,8 M
Net Debt 2022 25,9 M 35,1 M 35,1 M
P/E ratio 2022 -2,80x
Yield 2022 -
Capitalization 115 M 156 M 156 M
EV / Sales 2021 94,9x
EV / Sales 2022 7,88x
Nbr of Employees 72
Free-Float 62,5%
More Financials
Company
Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the... 
Sector
Pharmaceuticals
Calendar
03/31Earnings Release
More about the company
Ratings of Acacia Pharma Group plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ACACIA PHARMA GROUP PLC
2021Acacia Pharma Issues Ordinary Shares to its Employee Benefit Trust
AQ
2021ACACIA PHARMA GROUP PLC : Crossing thresholds
CO
2021CORRECTION : Issue of Shares to Employee Benefit Trust
AQ
2021Acacia Pharma Announces Successful Completion of BARHEMSYS Post-approval Requirement St..
AQ
2021Acacia Pharma Completes US FDA's Required Study for Post-Operative Drug With No Adverse..
MT
2021Acacia Pharma Completes Required Barhemsys Clinical Trial
DJ
2021Acacia Pharma Announces Successful Completion of BARHEMSYS« Post-approval Requirement S..
AQ
2021Acacia Pharma Announces Successful Completion of Barhemsys« Post-Approval Requirement S..
CI
2021Acacia Pharma to Present at the Jefferies London Healthcare Conference on 16 November 2..
PU
2021Acacia Pharma to Present at the Jefferies London Healthcare Conference
AQ
2021ACACIA PHARMA : Jefferies London Healthcare Conference Presentation
PU
2021ANALYST RECOMMENDATIONS : Acceleron Pharma, General Mills, Southwest Airlines, Home Depot,..
2021ACACIA PHARMA : Announces Submission and Validation of Marketing Authorization Application..
AQ
2021Acacia Pharma Group plc Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021ACACIA PHARMA : Mid-Year Presentation of Results for the Six Months ended 30 June 2021
PU
More news
News in other languages on ACACIA PHARMA GROUP PLC
01/21Brussel verder in het rood
01/20Brussel blijft in het rood
01/20Brussel koerst weer lager
01/20Degroof Petercam verlaagt koersdoel Acacia Pharma
01/19Brussel lager van start
More news
Analyst Recommendations on ACACIA PHARMA GROUP PLC
More recommendations
Chart ACACIA PHARMA GROUP PLC
Duration : Period :
Acacia Pharma Group plc Technical Analysis Chart | ACPH | GB00BYWF9Y76 | MarketScreener
Technical analysis trends ACACIA PHARMA GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 113,84 GBX
Average target price 600,90 GBX
Spread / Average Target 428%
EPS Revisions
Managers and Directors
Michael Bolinder Chief Executive Officer & Executive Director
Gary G. Gemignani Chief Financial Officer
Scott A. Byrd Chairman
Gabriel Fox Chief Medical Officer
John Robert Brown Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ACACIA PHARMA GROUP PLC6.92%156
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833